Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single and multiple ascending dose study of BI 1569912 in healthy Japanese males
jRCT2071210037Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in major depressive disorder (MDD) comparing BI 1569912 with Placebo (2 arms). Started Jul 2021; status: completed.
02
Drugs
BI 1569912
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2071210037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210037.